Published in Rheumatology (Oxford) on October 01, 2008
Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen (2009) 7.29
Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. Arthritis Rheumatol (2015) 1.84
Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro. J Cell Sci (2013) 1.03
New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J (2012) 0.99
The mitochondrial proteome: a dynamic functional program in tissues and disease states. Environ Mol Mutagen (2010) 0.93
Detection of differentially expressed basal cell proteins by mass spectrometry. Mol Cell Proteomics (2009) 0.92
Biomarkers in systemic sclerosis. Biomark Med (2010) 0.90
Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of human skin proteomic signatures. Exp Dermatol (2011) 0.87
Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol (2010) 0.84
Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9. J Invest Dermatol (2014) 0.84
A qualitative and quantitative proteomic study of human microdialysate and the cutaneous response to injury. AAPS J (2011) 0.82
A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS One (2015) 0.82
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther (2011) 0.79
Apoptosis modulation as a promising target for treatment of systemic sclerosis. Int J Rheumatol (2011) 0.78
Genomics and proteomics: Applications in autoimmune diseases. Pharmgenomics Pers Med (2009) 0.75
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet (2005) 4.14
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res (1999) 4.13
Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol (2000) 3.58
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol (1982) 3.08
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol (1992) 2.58
Population health and health care use: an information system for policy makers. Milbank Q (1996) 2.54
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Career differences between primary care and traditional trainees in internal medicine and pediatrics. Ann Intern Med (1992) 2.28
Alopecia universalis associated with a mutation in the human hairless gene. Science (1998) 2.23
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia (2006) 1.81
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
RNA regulatory element BLE1 directs the early steps of bicoid mRNA localization. Development (1993) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Variation in indications for cataract surgery in the United States, Denmark, Canada, and Spain: results from the International Cataract Surgery Outcomes Study. Br J Ophthalmol (1998) 1.64
HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS (1990) 1.62
A randomised controlled trial of a community intervention to prevent adolescent tobacco use. Tob Control (2000) 1.62
Role of IL-5 in innate and adaptive immunity to larval Strongyloides stercoralis in mice. J Immunol (2000) 1.61
Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand (1996) 1.55
Factor VIII related antigen in connective tissue disease patients and relatives. Br J Rheumatol (1990) 1.55
Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. Sex Transm Dis (2001) 1.54
International applicability of the VF-14. An index of visual function in patients with cataracts. Ophthalmology (1997) 1.51
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Marfan Database (third edition): new mutations and new routines for the software. Nucleic Acids Res (1998) 1.49
The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res (1995) 1.46
Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its interaction with utrophin. J Cell Sci (2000) 1.44
Somatic cell hybrids between mouse peritoneal macrophages and simian-virus-40-transformed human cells: II. Presence of human chromosome 7 carrying simin virus 40 genome in cells of tumors induced by hybrid cells. Proc Natl Acad Sci U S A (1975) 1.42
A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice. J Cell Biol (1996) 1.42
Community nurses' practices in managing perianal abscesses. J Wound Care (2008) 1.40
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum (2002) 1.40
Patients' acceptance of waiting for cataract surgery: what makes a wait too long? Soc Sci Med (1997) 1.39
Magnetic resonance imaging of osteitis condensans ilii. Br J Rheumatol (1994) 1.39
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol (1995) 1.38
Visual outcomes of cataract surgery in the United States, Canada, Denmark, and Spain. Report From the International Cataract Surgery Outcomes Study. Arch Ophthalmol (1998) 1.38
Nucleotide sequence of the gene coding for a 130-kDa mosquitocidal protein of Bacillus thuringiensis israelensis. Gene (1988) 1.36
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
Serology of Lyme disease. Lancet (1986) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) (2009) 1.29
N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM (2005) 1.28
IL-4- and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. J Immunol (1994) 1.28
Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol (1996) 1.27
Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice. Exp Parasitol (1996) 1.27
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Continuity of pediatric ambulatory care in a universally insured population. Pediatrics (1996) 1.25
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
New opportunities for Chlamydia prevention: applications of science to public health practice. Sex Transm Dis (1995) 1.16
Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol (1993) 1.16
Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells. Proc Natl Acad Sci U S A (1984) 1.16
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2012) 1.13
Managing health services: how the Population Health Information System (POPULIS) works for policymakers. Med Care (1999) 1.12
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol (1995) 1.12
Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res (1995) 1.11
Xq-Yq interchange resulting in supernormal X-linked gene expression in severely retarded males with 46,XYq- karyotype. Nat Genet (1994) 1.11
IL-12 eliminates the Th-2 dependent protective immune response of mice to larval Strongyloides stercoralis. Parasite Immunol (1997) 1.11
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum (1999) 1.10
Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and squamous cell carcinoma cells. Proc Natl Acad Sci U S A (1991) 1.10
Willingness to pay to shorten waiting time for cataract surgery. Health Aff (Millwood) (1997) 1.10
Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum (1994) 1.10
exl protein specifically binds BLE1, a bicoid mRNA localization element, and is required for one phase of its activity. Proc Natl Acad Sci U S A (1995) 1.10
Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol (1993) 1.09
The value of SPECT scans in identifying back pain likely to benefit from facet joint injection. Br J Rheumatol (1996) 1.09
PrP gene dosage and long term potentiation. Neurodegeneration (1995) 1.09
The cardiovascular acitivity of ICI 118,587 a novel beta-adrenoceptor partial agonist [proceedings]. Br J Pharmacol (1979) 1.09
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J (2009) 1.08
Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis (1992) 1.08
Minority women and tobacco: implications for smoking cessation interventions. Ann Behav Med (1997) 1.07
How many general surgeons do you need in rural areas? Three approaches to physician resource planning in southern Manitoba. CMAJ (1996) 1.07
The catabolism of mammalian glycoproteins. Comparison of the storage products in bovine, feline and human mannosidosis. Biochem J (1983) 1.07
Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem (1984) 1.07
Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess (2012) 1.07
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis (2007) 1.07
Inhibition of lipid biosynthesis induces the expression of the pspA gene. Microbiology (1994) 1.06
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis (2001) 1.06
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res (2001) 1.05
Cross-cultural differences in the reporting of global functional capacity: an example in cataract patients. Med Care (1998) 1.05
Increased incidence of spontaneous abortion and infertility in women with scleroderma before disease onset: a controlled study. Ann Rheum Dis (1988) 1.05
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis (2008) 1.05